Hear now. And always

Cochlear on implantoitavien kuulolaitteiden johtava yritys, jonka tuotteet auttavat palauttamaan kuulon ja yhdistämään ihmiset äänten maailmaan

Employees

5001-10000

Funding

Growth

AI Classification

HealthcareMedDevice

Cochlear Limited is a publicly listed Australian medical device company (ASX: COH) and global market leader with ~60% share in cochlear implants, designing and manufacturing implantable hearing solutions including the Nucleus cochlear implant system, Baha bone conduction implant, and Hybrid electro-acoustic implant. The company serves 650,000+ implant recipients across 180+ countries, distributing through audiologists, ENT clinics, and hospitals.

Deep Intelligence

Buying Signals

Launched Nucleus Nexa System in 2025 — world's first and only smart cochlear implant with upgradeable internal firmware, representing a major platform investment requiring associated software and infrastructure support
Launched Nucleus 8 Sound Processor in November 2024 with direct Apple/Android streaming, signaling significant connected-device and digital capability investment
Completed acquisition of Oticon Medical's cochlear implant business in May 2024, adding 20,000+ customers and triggering complex systems, data, and customer integration workstreams
Investing approximately $270 million USD annually in R&D (~12% of revenue), indicating sustained organizational growth and technology spending
Cochlear North America won dual gold awards at the Hearing Health & Technology Matters Innovator Awards in October 2025, reflecting competitive positioning and marketing investment

Account Scoring

Tier ALow Churn RiskProduct Launch

Pain Signals

Oracle E-Business Suite detected in tech stack — a legacy ERP platform that creates integration complexity with modern cloud-native systems and could be a modernization pressure point
Integration of 20,000+ Oticon Medical customers following the May 2024 acquisition introduces significant data consolidation, CRM migration, and customer lifecycle management challenges
Emerging fully implantable cochlear implant trials by MUSC and Envoy Medical represent a potential disruptive threat to Cochlear's current product architecture and market position